Abstract:Objectives To describe the severity and impact of gastrointestinal involvement in patients with systemic sclerosis (SSc) and identify associated factors. Patients and methods Non-controlled cross-sectional study of patients with SSc (2013 American College of Rheumatology/European League Against Rheumatism criteria). The main variables were severity of gastrointestinal involvement according to the University of California, Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument (UCLA SCTC GIT 2.0) and dysphagia according to the Eating Assessment Tool-10 (EAT-10). We evaluated reflux, distension, diarrhoea, faecal soilage, constipation, emotional well-being and social functioning, as well as dysphagia. Clinical and epidemiological data were collected using the Mini Nutritional Assessment Short Form (MNA-SF) and the EuroQol-5D-3L. The degree of skin fibrosis was assessed using the modified Rodnan skin score (mRSS). Multivariate models were constructed to analyse factors associated with gastrointestinal involvement and dysphagia. Results Of the 75 patients with SSc included, 58.7% had moderate, severe or very severe reflux, 57.4% had constipation according to UCLA SCTC GIT 2.0 and 49.7% had abdominal distension. Gastrointestinal symptoms interfered significantly with social functioning (42.7%) and emotional well-being (40.0%). Dysphagia (EAT-10≥3) was recorded in 52% of patients, and according to MNA-SF poor nutrition in 30.7%, and clear malnutrition requiring a nutritional intervention in 5.3%. Multivariate adjustment revealed an association between severity of gastrointestinal symptoms according to the mRSS (β=0.249; p=0.002) and Visual Analogue Scale 3-Level EuroQol-5D (VAS-EQ-5D-3L) (β=–0.302; p=0.001), whereas presence of dysphagia was associated with the mRSS (OR=2.794; p=0.015), VAS-EQ-5D-3L (OR=0.950; p=0.005) and malnutrition (MNA-SF≤7; OR=3.920; p=0.041). Conclusions Patients with SSc frequently present severe gastrointestinal symptoms. These are associated with poor quality of life, more severe skin involvement and malnutrition.

The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes

Expression of Epidermal Growth Factor receptor (EGFR) in Systemic Sclerosis patients (SSc) and Gastro-oesophageal Reflux Disease (GORD)

Prevalence and outcomes of gastrointestinal manifestations in an Australian Scleroderma cohort

Gastrointestinal disease in systemic sclerosis: the neglected organ system?

Pulmonary manifestations of gastroesophageal reflux disease

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies

Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study

Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry

Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials

The role of screening of patients proved to have gastroesophageal reflux disease by upper gastrointestinal endoscope for early detection of interstitial lung diseases

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial

Gastrointestinal disorders in systemic sclerosis: cluster analysis and prognosis from a French prospective cohort

Impact of gastrointestinal symptoms and psychological distress on quality of life in systemic sclerosis: a cross-sectional study

Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach

A multi-national survey to identify clinicians' perspectives concerning Proton Pump Inhibitors in patients with Systemic Sclerosis

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Efficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease

The Treatment of Lung Involvement in Systemic Sclerosis

Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study

Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis